{"id":4203,"count":2,"description":"<strong>Tuberkul\u00f3za (TB)<\/strong> z\u016fst\u00e1v\u00e1 jednou z nejnebezpe\u010dn\u011bj\u0161\u00edch infek\u010dn\u00edch chorob na sv\u011bt\u011b \u2014 WHO odhaduje, \u017ee v roce 2022 onemocn\u011blo tuberkul\u00f3zou 10,6 milionu lid\u00ed a 1,3 milionu zem\u0159elo, v\u010detn\u011b 167 000 s koinfekc\u00ed HIV. Onemocn\u011bn\u00ed je zp\u016fsobeno <em>Mycobacterium tuberculosis<\/em>, pomalu rostouc\u00ed intracelul\u00e1rn\u00ed ty\u010dinkou, kter\u00e1 prim\u00e1rn\u011b postihuje pl\u00edce, ale m\u016f\u017ee zas\u00e1hnout t\u00e9m\u011b\u0159 jak\u00fdkoli org\u00e1nov\u00fd syst\u00e9m. <strong>Modern\u00ed kr\u00e1tkodob\u00e1 l\u00e9\u010dba TB je pln\u011b l\u00e9\u010debn\u00e1 \u2014 ale pouze p\u0159i spr\u00e1vn\u00e9m pou\u017eit\u00ed<\/strong>: spr\u00e1vn\u00e1 kombinace l\u00e9k\u016f, ve spr\u00e1vn\u00e9 d\u00e1vce, po celou dobu, pod odborn\u00fdm dohledem. Tato str\u00e1nka uv\u00e1d\u00ed antituberkulotika skladem v MedsBase. <strong>Nen\u00ed to n\u00e1vod k samol\u00e9\u010db\u011b aktivn\u00ed TB.<\/strong>\nThe 4-drug RIPE regimen\nThe WHO standard regimen for new, drug-susceptible pulmonary tuberculosis is six months in two phases:\n<strong>Intenzivn\u00ed f\u00e1ze \u2014 2 m\u011bs\u00edce:<\/strong> Rifampicin + Isoniazid + Pyrazinamid + <strong>Ethambutol<\/strong> (RIPE), v\u0161echny \u010dty\u0159i l\u00e9ky denn\u011b.<strong>Pokra\u010dovac\u00ed f\u00e1ze \u2014 4 m\u011bs\u00edce:<\/strong> Rifampicin + Isoniazid (RH), continued daily.\nLonger regimens (9&ndash;12 months) apply to TB meningitis, bone and joint TB, and disseminated disease. Treatment is supervised &mdash; <strong>p\u0159\u00edmo pozorovan\u00e1 terapie (DOT)<\/strong> is recommended in most national programmes to ensure adherence and to prevent the emergence of multidrug-resistant TB (MDR-TB).\nWhy combination therapy is mandatory\nSingle-agent treatment of active TB inevitably selects for resistant organisms. The bacterial load in a cavitating pulmonary lesion is enormous (up to 109 bacilli) and naturally occurring resistance mutations exist at low frequency for every drug. Using one drug kills the susceptible majority and leaves the resistant minority to multiply &mdash; treatment failure with a now-untreatable strain. <strong>Kombinovan\u00e1 terapie<\/strong> funguje, proto\u017ee pravd\u011bpodobnost, \u017ee jeden organismus bude sou\u010dasn\u011b rezistentn\u00ed k v\u00edce l\u00e9k\u016fm, je miziv\u011b mal\u00e1. Proto ka\u017ed\u00e1 str\u00e1nka v t\u00e9to kategorii nese explicitn\u00ed varov\u00e1n\u00ed, \u017ee n\u00e1kup jednoho l\u00e9ku je vhodn\u00fd <strong>pouze<\/strong> for ongoing supervised regimen continuation, latent TB infection (4-month rifampicin monotherapy), or specific non-TB indications such as leprosy, MAC, or meningococcal prophylaxis.\nMultidrug-resistant TB &mdash; a warning\nMDR-TB &mdash; resistance to at least rifampicin and isoniazid &mdash; affected an estimated 410,000 people worldwide in 2022. MDR-TB requires longer treatment (9&ndash;20 months) with second-line agents including <strong>fluorochinolon\u016f<\/strong> (levofloxacin, moxifloxacin), <strong>linezolidu<\/strong>, <strong>bedaquilinu<\/strong>, a <strong>klofaziminu<\/strong>. MDR-TB is the predictable downstream result of partial, irregular, or single-agent treatment of drug-susceptible TB. Cure is possible but harder, more expensive, and more toxic than first-line therapy &mdash; the case for getting the initial regimen right and completing it.\nAnti-TB medications stocked at MedsBase\nThis category currently lists <strong>dv\u011b ze \u010dty\u0159 l\u00e9k\u016f prvn\u00ed linie<\/strong>:\n<a href=\"https:\/\/medsbase.com\/cs\/r-cin\/\"><strong>R-Cin<\/strong><\/a> \u2014 <strong>rifampicin 300\/450\/600 mg<\/strong> (Cipla). Nejv\u00fdznamn\u011bj\u0161\u00ed steriliza\u010dn\u00ed l\u00e9k v terapii tuberkul\u00f3zy. Pou\u017e\u00edv\u00e1 se tak\u00e9 jako 4m\u011bs\u00ed\u010dn\u00ed monoterapie pro latentn\u00ed tuberkul\u00f3zn\u00ed infekci (re\u017eim 4R), u multibacil\u00e1rn\u00ed lepry v r\u00e1mci multilekov\u00e9 terapie, pro meningokokovou profylaxi kontakt\u016f a u z\u00e1va\u017en\u00fdch stafylokokov\u00fdch infekc\u00ed kost\u00ed, kloub\u016f nebo prot\u00e9z. Rifampicin je <strong>siln\u00fd induktor CYP3A4 \/ CYP2C9 \/ CYP2C19<\/strong> \u2014 sni\u017euje \u00fa\u010dinnost des\u00edtek sou\u010dasn\u011b pod\u00e1van\u00fdch l\u00e9k\u016f v\u010detn\u011b peror\u00e1ln\u00edch kontraceptiv, warfarinu, DOAC, statin\u016f, metadonu, imunosupresiv po transplantaci, antiretrovirotik a mnoha dal\u0161\u00edch. <strong>P\u0159ed zah\u00e1jen\u00edm l\u00e9\u010dby v\u017edy sd\u011blte v\u0161echny sou\u010dasn\u011b u\u017e\u00edvan\u00e9 l\u00e9ky.<\/strong> Zp\u016fsobuje oran\u017eovo-\u010derven\u00e9 zabarven\u00ed mo\u010di, potu, slz a slin (ne\u0161kodn\u00e9, ale trvale barv\u00ed m\u011bkk\u00e9 kontaktn\u00ed \u010do\u010dky).<a href=\"https:\/\/medsbase.com\/cs\/combutol\/\"><strong>Combutol<\/strong><\/a> \u2014 <strong>ethambutol HCl 200\/400\/800 mg<\/strong> (Lupin). Bakteriostatick\u00fd prost\u0159edek, jeho\u017e \u00falohou v re\u017eimu je potla\u010dit vznik rezistence na baktericidn\u00ed partnersk\u00e9 l\u00e9ky. Tak\u00e9 z\u00e1kladn\u00ed l\u00e9k pro infekci komplexem Mycobacterium avium (MAC) u HIV. Charakteristickou toxicitou je <strong>d\u00e1vkov\u011b z\u00e1visl\u00e1 optick\u00e1 neuritida<\/strong>: ztr\u00e1ta zrakov\u00e9 ostrosti a rozli\u0161en\u00ed \u010derven\u00e9 a zelen\u00e9 barvy, obvykle reverzibiln\u00ed, pokud je l\u00e9k vysazen p\u0159i prvn\u00edm p\u0159\u00edznaku, ale potenci\u00e1ln\u011b trval\u00e1, pokud nen\u00ed. <strong>Z\u00e1kladn\u00ed oftalmologick\u00e9 vy\u0161et\u0159en\u00ed + m\u011bs\u00ed\u010dn\u00ed kontroly zraku jsou povinn\u00e9.<\/strong> Renal-dose adjustment is essential.\nThe other two first-line agents &mdash; <strong>isoniazid<\/strong> a <strong>pyrazinamid<\/strong> &mdash; are not currently stocked at MedsBase. Patients on a full RIPE regimen will need to source these from another supplier, a hospital pharmacy, or their national TB programme. National TB programmes in most countries provide first-line TB drugs free of charge.\nMandatory monitoring during TB therapy\n<strong>Funkce jater<\/strong> \u2014 v\u00fdchoz\u00ed a alespo\u0148 m\u011bs\u00ed\u010dn\u011b. Rifampicin, isoniazid a pyrazinamid jsou v\u0161echny hepatotoxick\u00e9; kombinovan\u00fd re\u017eim zp\u016fsobuje klinicky v\u00fdznamnou hepatitidu p\u0159ibli\u017en\u011b u 5 % pacient\u016f. P\u0159i \u017eloutence, tmav\u00e9 mo\u010di nebo bolesti v prav\u00e9m horn\u00edm kvadrantu b\u0159icha p\u0159eru\u0161te re\u017eim a vyhledejte kontrolu.<strong>Zrakov\u00e1 ostrost a barvocit<\/strong> \u2014 v\u00fdchoz\u00ed a m\u011bs\u00ed\u010dn\u011b b\u011bhem u\u017e\u00edv\u00e1n\u00ed ethambutolu. P\u0159i jak\u00e9koli nov\u00e9 st\u00ed\u017enosti na zrak okam\u017eit\u011b p\u0159eru\u0161te u\u017e\u00edv\u00e1n\u00ed ethambutolu.<strong>Vy\u0161et\u0159en\u00ed sputa a kultivace<\/strong> \u2014 hlavn\u00ed ukazatel \u00fa\u010dinnosti u aktivn\u00ed plicn\u00ed tuberkul\u00f3zy; p\u0159echod na negativn\u00ed kultivaci do 2 m\u011bs\u00edc\u016f ukazuje na dobrou odpov\u011b\u010f.<strong>Funkce ledvin a s\u00e9rov\u00e1 kyselina mo\u010dov\u00e1<\/strong> \u2014 clearance ethambutolu je ren\u00e1ln\u00ed; pyrazinamid zvy\u0161uje hladinu kyseliny mo\u010dov\u00e9 a m\u016f\u017ee vyvolat dnu.<strong>HIV status<\/strong> &mdash; TB-HIV co-infection alters the regimen, the drug interactions, and the prognosis. Every patient with active TB should be offered HIV testing.\nWho this category is not for\nIf you have suspected active TB (chronic cough &gt; 3 weeks, weight loss, night sweats, blood-stained sputum) you need a TB specialist, sputum testing, susceptibility testing, contact tracing, and combination therapy under directly observed treatment &mdash; <strong>ne samol\u00e9\u010dbu jedn\u00edm l\u00e9kem<\/strong>. Nel\u00e9\u010den\u00e1 nebo \u010d\u00e1ste\u010dn\u011b l\u00e9\u010den\u00e1 aktivn\u00ed tuberkul\u00f3za je naka\u017eliv\u00e1, zabije p\u0159ibli\u017en\u011b polovinu naka\u017een\u00fdch a je nej\u010dast\u011bj\u0161\u00ed p\u0159\u00ed\u010dinou vzniku MDR-TB. Tuto str\u00e1nku pou\u017eijte pro dopl\u0148ov\u00e1n\u00ed a pokra\u010dov\u00e1n\u00ed v ji\u017e zah\u00e1jen\u00e9 l\u00e9\u010db\u011b pod dohledem, pro l\u00e9\u010dbu latentn\u00ed tuberkul\u00f3zn\u00ed infekce nebo pro specifick\u00e9 indikace net\u00fdkaj\u00edc\u00ed se TB uveden\u00e9 na ka\u017ed\u00e9 produktov\u00e9 str\u00e1nce.","link":"https:\/\/medsbase.com\/cs\/tuberculosis-treatment\/","name":"L\u00e9\u010dba tuberkul\u00f3zy","slug":"tuberculosis-treatment","taxonomy":"product_cat","parent":3223,"meta":[],"menu_order":0,"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product_cat\/4203","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product_cat"}],"about":[{"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/taxonomies\/product_cat"}],"up":[{"embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product_cat\/3223"}],"wp:post_type":[{"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product?product_cat=4203"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}